Clinical trials
Lupus Erythematosus, Systemic clinical trials
Below are recruiting lupus erythematosus, systemic clinical trials, each written for real people, not researchers. We’re tracking 264 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06513429Recruiting
IM19 CAR-T cell therapy for tough lupus cases
This trial tests whether a new type of immune cell therapy, called IM19 CAR-T, can help people with lupus that hasn't gotten better with standard treatments. It is designed for people ages 18 to 65 with moderate to severe disease activity.
Beijing, Beijing MunicipalityAges 18–65 - NCT06544343Recruiting
Remote monitoring for new immunosuppressive therapy
This trial tests whether regular remote check-ins can help manage chronic immunosuppressive medications. If you have an autoimmune condition like rheumatoid arthritis or lupus and are starting a new medicine such as methotrexate or a biologic, you may be eligible.
Perugia, PGAges Any age - NCT06551389Recruiting
Lupus follow-up study at Brest Hospital
This study follows people with systemic lupus erythematosus (an autoimmune disease) who are seen in a special clinic. It aims to track their health over time.
BrestAges 18 years+ - NCT06559163RecruitingPhase 2
Obexelimab for active lupus (SLE) trial
This trial is testing an investigational drug called obexelimab for people with active lupus (SLE) who are already on standard lupus treatments. It aims to see if the drug can help control lupus activity better than current medications alone.
Fresno, CaliforniaAges 18–70 - NCT06576271RecruitingPhase 1
Testing a new drug for lupus and related lung disease
This study tests an experimental drug called GSK4527363. It is first being given to healthy volunteers to check safety, then to people with lupus (SLE) and people with connective tissue disease-related lung disease (CTD-ILD). The goal is to see if the drug is safe and how the body processes it.
Scottsdale, ArizonaAges 18–65 - NCT06581198RecruitingPhase 2
CAR-T cell therapy for lupus or lupus nephritis
This trial tests a new CAR-T cell treatment called rapcabtagene autoleucel for people with active lupus or lupus nephritis that hasn't improved with at least two standard therapies. It aims to reduce disease activity and may offer a new option for hard-to-treat cases.
Birmingham, AlabamaAges 18–75 - NCT06585514RecruitingPhase 1/Phase 2
CAR T-cell therapy for hard-to-treat lupus
This trial tests a treatment where your own immune cells are modified to attack and destroy lupus-causing B cells. It's for people with lupus (SLE) that hasn't improved with standard treatments.
Beijing, Beijing MunicipalityAges 3–65 - NCT06593041Recruiting
Platelets in lupus and other autoimmune diseases
This study looks at how platelets (small blood cells that help with clotting) might play a role in autoimmune diseases like lupus. By understanding this, researchers hope to find new ways to treat these conditions.
Strasbourg, FranceAges 18–70 - NCT06133972RecruitingPhase 3
Long-term safety of ianalumab for lupus (extension study)
This extension study tests the long-term safety of ianalumab for people with systemic lupus erythematosus. If you completed a prior SIRIUS-SLE study and your doctor thinks you'd benefit, you may continue treatment for up to 60 more weeks.
Anniston, AlabamaAges 12–100 - NCT07509892RecruitingPhase 2
Testing TQH3906 for people with active lupus
This study tests a new medicine, TQH3906, in people with systemic lupus erythematosus (SLE) who have moderate to severe disease activity. It aims to see if TQH3906 can safely reduce lupus symptoms like joint pain, skin rash, or vasculitis.
Bengbu, AnhuiAges 18–74 - NCT06613360RecruitingPhase 1
Study of CLN-978 for people with systemic lupus erythematosus
This trial tests an experimental drug called CLN-978, given as a shot under the skin, that targets a protein on certain immune cells (B cells) to try to calm overactive immune activity in lupus. The goal is to see if it can reduce lupus symptoms for people whose disease has not been controlled by other treatments.
Avondale, ArizonaAges 18–70 - NCT06625671RecruitingPhase 1/Phase 2
DB-2304 antibody injection for lupus skin disease (SLE/CLE)
This trial tests an experimental antibody injection (DB-2304) to see if it can improve lupus skin rashes and other lupus symptoms. It is for people with active lupus skin disease who have already tried standard treatments.
La Palma, CaliforniaAges 18–70 - NCT06653556RecruitingEarly Phase 1
LCAR-AIO for relapsed or hard-to-treat lupus
This study tests a new treatment called LCAR-AIO for people with systemic lupus erythematosus (SLE) that has come back or not responded well to standard therapies. The goal is to see if it can help control the disease.
Wuhan, HubeiAges 18–65 - NCT06675422RecruitingPhase 1/Phase 2
JY231 injection for active lupus
This trial tests an investigational drug called JY231 for people with active systemic lupus erythematosus (SLE) that is not well controlled with standard treatments. The goal is to see if JY231 can reduce lupus activity and improve symptoms.
Kunming, YunnanAges 14–75 - NCT06676631RecruitingPhase 1
NK cells plus rituximab for active lupus
This study tests whether combining immune cells (NK cells) with rituximab can help people with hard-to-treat lupus or lupus-related kidney disease. It is for patients whose lupus is still active despite standard treatments.
Guangzhou, GuangdomgAges 18–65 - NCT06685042RecruitingPhase 1/Phase 2
CAR T-cell therapy for severe autoimmune diseases
This study tests a new treatment called CAR T-cell therapy for people with severe autoimmune diseases that haven't gotten better with standard treatments. The goal is to see if it can help control the disease by reprogramming your immune cells.
Rome, LazioAges 18–65 - NCT06691152RecruitingPhase 1
CD19 UCAR T cells for severe lupus
This trial tests an experimental treatment called CD19 UCAR T cells for people with severe lupus that hasn't gotten better with standard medicines. It aims to see if these special immune cells can safely and effectively control the disease.
Hangzhou, ZhejiangAges 5 years+ - NCT06708845RecruitingPhase 1
Zamto-cel cell therapy for autoimmune diseases
This early-phase trial tests a new cell therapy called Zamto-cel for people with lupus (with or without kidney inflammation) or systemic sclerosis (hardening of the skin and internal organs). It is for those whose condition has not improved enough after standard treatments.
Milwaukee, WisconsinAges 18 years+ - NCT06710717RecruitingPhase 1
CD19 CAR T-cells for severe lupus
This early-phase trial tests whether a patient's own immune cells (T-cells) that are modified to target a protein called CD19 can help people with severe lupus that hasn't improved with other treatments. The goal is to reduce lupus activity and possibly achieve remission.
Bandar Tun Razak, Kuala LumpurAges 18–65 - NCT06737380RecruitingPhase 1
Stem Cell Therapy Study for Active Lupus
This study tests whether a special type of stem cell treatment (called UC-MSC) can help calm lupus when standard medicines aren't enough. It's for people with active lupus who have tried other non-steroid medications.
Charleston, South CarolinaAges 18–75 - NCT06789107RecruitingPhase 1
Blinatumomab for severe childhood lupus
This trial tests a drug called blinatumomab for children with active lupus that hasn't improved with standard treatments. It aims to see if this immunotherapy can help calm the immune system and reduce lupus activity.
Hangzhou, ZhejiangAges 5 years+ - NCT06794008RecruitingPhase 2
CAR-T cell therapy for hard-to-treat autoimmune diseases
This trial tests a new treatment using your own immune cells (called CAR-T cells) designed to target and attack cells that cause autoimmune diseases. It is for people with lupus, Sjögren's syndrome, inflammatory myopathy, scleroderma, Behcet's disease, ANCA-associated vasculitis, IgG4-related disease, antiphospholipid syndrome, or thrombotic thrombocytopenic purpura who have not improved with standard therapies.
Beijing, Beijing MunicipalityAges 18–65 - NCT06796569Recruiting
Blood test for inflammation in lupus patients
This study looks at a simple blood test (called the Systemic Immune Inflammatory Index) to see if it can help doctors understand how active lupus is in your body. It includes people with lupus, especially those with kidney involvement, to find better ways to track the disease.
Sohag, Sohag GovernorateAges 16 years+ - NCT06804057Recruiting
SLE drug safety registry for adults with lupus
This registry tracks the safety and effectiveness of lupus treatments over time. If you have SLE and are starting a new treatment or were recently diagnosed, joining helps doctors learn which medicines work best.
Waltham, MassachusettsAges 18 years+
Hear when a new Lupus Erythematosus, Systemic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lupus erythematosus, systemic?
- Yes. Clin2 currently lists 264 recruiting lupus erythematosus, systemic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lupus erythematosus, systemic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lupus erythematosus, systemic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.